Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis

被引:0
作者
Yang Jiao
Yan Lu
Xiao-ying Li
机构
[1] Shanghai Institute of Endocrinology and Metabolism,Department of Endocrine and Metabolic Diseases
[2] Shanghai Clinical Center for Endocrine and Metabolic Diseases,The Key Laboratory of Endocrine Tumors and the Division of Endocrine and Metabolic Diseases
[3] Ruijin Hospital,undefined
[4] Shanghai Jiao Tong University School of Medicine,undefined
[5] E-Institute of Shanghai Universities,undefined
来源
Acta Pharmacologica Sinica | 2015年 / 36卷
关键词
farnesoid X receptor; non-alcoholic fatty liver disease; liver; triglyceride metabolism; glucose metabolism; drug discovery;
D O I
暂无
中图分类号
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is characterized by the aberrant accumulation of triglycerides in hepatocytes in the absence of significant alcohol consumption, viral infection or other specific causes of liver disease. NAFLD has become a burgeoning health problem both worldwide and in China, but its pathogenesis remains poorly understood. Farnesoid X receptor (FXR), a member of the nuclear receptor (NR) superfamily, has been demonstrated to be the primary sensor for endogenous bile acids, and play a crucial role in hepatic triglyceride homeostasis. Deciphering the synergistic contributions of FXR to triglyceride metabolism is critical for discovering therapeutic agents in the treatment of NAFLD and hypertriglyceridemia.
引用
收藏
页码:44 / 50
页数:6
相关论文
共 50 条
  • [31] Hepatic farnesoid X receptor is necessary to facilitate ductular reaction and expression of heme biosynthetic genes
    Dean, Angela E.
    Jungwirth, Emilian
    Panzitt, Katrin
    Wagner, Martin
    Anakk, Sayeepriyadarshini
    HEPATOLOGY COMMUNICATIONS, 2023, 7 (10)
  • [32] An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
    Xie, Cen
    Jiang, Changtao
    Shi, Jingmin
    Gan, Xiaoxia
    Sun, Dongxue
    Sun, Lulu
    Wang, Ting
    Takahashi, Shogo
    Anitha, Mallappa
    Krausz, Kristopher W.
    Patterson, Andrew D.
    Gonzalez, Frank J.
    DIABETES, 2017, 66 (03) : 613 - 626
  • [33] Farnesoid X Receptor Activation Modulates Calcium Homeostasis in Rat Aortic Vascular Smooth Muscle Cells
    Zhang, Ran
    Peng, Liang
    Ran, Haihong
    Fan, Yongyan
    Zhao, Yu
    Cao, Feng
    CHINESE JOURNAL OF PHYSIOLOGY, 2018, 61 (04): : 210 - 220
  • [34] Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice
    Massafra, Vittoria
    Milona, Alexandra
    Vos, Harmjan R.
    Ramos, Ruben J. J.
    Gerrits, Johan
    Willemsen, Ellen C. L.
    Pittol, Jose M. Ramos
    Ijssennagger, Noortje
    Houweling, Martin
    Prinsen, Hubertus C. M. T.
    Verhoeven-Duif, Nanda M.
    Burgering, Boudewijn M. T.
    van Mil, Saskia W. C.
    GASTROENTEROLOGY, 2017, 152 (06) : 1462 - +
  • [35] Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease
    Gonzalez, Frank J.
    Jiang, Changtao
    Xie, Cen
    Patterson, Andrew D.
    DIGESTIVE DISEASES, 2017, 35 (03) : 178 - 184
  • [36] Makisterone A attenuates experimental cholestasis by activating the farnesoid X receptor
    Kang, Peiyuan
    Li, Sha
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 623 : 162 - 169
  • [37] Astaxanthin as a metabolic regulator of glucose and lipid homeostasis
    Medoro, Alessandro
    Intrieri, Mariano
    Passarella, Daniela
    Willcox, Donald Craig
    Davinelli, Sergio
    Scapagnini, Giovanni
    JOURNAL OF FUNCTIONAL FOODS, 2024, 112
  • [38] Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
    Kim, Teayoun
    Nason, Shelly
    Holleman, Cassie
    Pepin, Mark
    Wilson, Landon
    Berryhill, Taylor F.
    Wende, Adam R.
    Steele, Chad
    Young, Martin E.
    Barnes, Stephen
    Drucker, Daniel J.
    Finan, Brian
    DiMarchi, Richard
    Perez-Tilve, Diego
    Tschoep, Matthias
    Habegger, Kirk M.
    DIABETES, 2018, 67 (09) : 1773 - 1782
  • [39] Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis
    Tadashi Namisaki
    Kosuke Kaji
    Naotaka Shimozato
    Daisuke Kaya
    Takahiro Ozutsumi
    Yuki Tsuji
    Yukihisa Fujinaga
    Koh Kitagawa
    Masanori Furukawa
    Shinya Sato
    Yasuhiko Sawada
    Norihisa Nishimura
    Hiroaki Takaya
    Yasushi Okura
    Kenichiro Seki
    Hideto Kawaratani
    Kei Moriya
    Ryuichi Noguchi
    Kiyoshi Asada
    Takemi Akahane
    Akira Mitoro
    Hitoshi Yoshiji
    Indian Journal of Gastroenterology, 2022, 41 : 169 - 180
  • [40] Farnesoid X receptor as a therapeutic target for dyslipidemia
    Evans, Mark J.
    Gardell, Stephen J.
    CLINICAL LIPIDOLOGY, 2009, 4 (05) : 587 - 594